FORT
MYERS, Fla., April 25,
2024 /PRNewswire/ -- Florida Cancer Specialists
& Research Institute, LLC (FCS) medical oncologist and
hematologist Ernesto
Bustinza-Linares, MD is co-author of a recent abstract
published in the American Society of Clinical Oncology Journal, JCO
Precision Oncology, that uncovers a new testing method to determine
personalized care options for patients with metastatic non-small
cell lung cancer (NSCLC).
"We cannot stress enough the importance of research in the
oncology field," says FCS President & Managing Physician
Lucio N. Gordan, MD. "Furthermore,
our own physicians are making remarkable strides in advancing
oncology care for patients. By incorporating precision oncology
tactics, we are uncovering new applications of existing therapies
to drive the best results, as was done in this study."
The abstract's authors address the limitations of existing
guidelines that recommend checkpoint immunotherapy, sometimes in
combination with chemotherapy, for treating NSCLC, which often
discounts patient variability and immune factors. Using a new
machine-learning test for pretreated plasma proteomic profiles,
PROphet, the authors were able to identify levels of protein
inhibitors for each patient to determine the best line of
treatment.
The findings from the study show that by incorporating
additional plasma proteome-based testing, combined with the
standard protein inhibitor testing, clear differences in patient
outcomes were observed after applying targeted treatments based on
the testing results.
"We can no longer apply a blanketed approach to oncology care,"
says Dr. Bustinza. "This study is pivotal in developing a precise
approach to treating cancer based on the unique cellular properties
of the patient, not the cancer type. With this knowledge, we can
then apply the best possible approach, in this instance, choosing a
monotherapy or combination therapy, to drive optimal results."
To read the full abstract, visit:
https://ascopubs.org/doi/full/10.1200/PO.23.00555.
About Florida Cancer Specialists & Research Institute,
LLC: (FLCancer.com)
Florida Cancer Specialists & Research Institute (FCS) offers
patients access to more clinical trials than any private oncology
practice in Florida. The majority
of new cancer drugs recently approved for use in the U.S. were
studied in clinical trials with FCS participation.* Recognized for
our research, FCS is a recipient of the national Clinical Trials
Participation Award presented by the American Society of Clinical
Oncology (ASCO). FCS physicians, trained in prestigious medical
schools and research institutes, are consistently ranked nationally
as Top Doctors by U.S. News & World Report.
Celebrating its 40th year in 2024, FCS has built a
national reputation for excellence that is reflected in exceptional
and compassionate patient care, driven by innovative clinical
research, cutting-edge technologies and advanced treatments,
including targeted therapies genomic-based treatment and
immunotherapy. Our highest values are embodied by our outstanding
team of highly trained and dedicated physicians, clinicians and
staff.
*Prior to approval
View original content to download
multimedia:https://www.prnewswire.com/news-releases/new-clinical-study-identifies-personalized-treatment-options-for-metastatic-non-small-cell-lung-cancer-with-plasma-proteome-testing-302127687.html
SOURCE Florida Cancer Specialists & Research Institute